What is Healthy io?
Healthy.io operates at the intersection of mobile technology and clinical diagnostics. By utilizing proprietary computer vision algorithms, the company enables patients to perform accurate medical tests—such as chronic kidney disease monitoring and urinary tract infection screening—using only their smartphone cameras. This approach effectively democratizes access to high-quality healthcare, shifting the paradigm from centralized laboratory testing to decentralized, home-based care.
The company's market position is defined by its ability to integrate seamlessly into existing healthcare workflows, providing clinicians with actionable data while reducing the burden on healthcare systems. As a leader in the digital health space, Healthy.io is not merely a software provider but a critical infrastructure partner for health systems aiming to improve patient outcomes through proactive, data-driven interventions.
How much funding has Healthy io raised?
Healthy io has raised a total of $140M across 4 funding rounds:
Series A
$12M
Series B
$18M
Series C
$60M
Series D
$50M
Series A (2017): $12M with participation from Quantum Pacific Capital
Series B (2019): $18M, investors not publicly disclosed
Series C (2019): $60M supported by Corner Ventures, Samsung NEXT, Ansonia Holdings, Aleph, and Joy Capital
Series D (2023): $50M featuring Schusterman Family Investments and Aleph
Key Investors in Healthy io
Aleph
Aleph is an early stage venture capital fund that partners with entrepreneurs to help scale them into large, meaningful companies and globally recognized brands.
Samsung NEXT
Samsung NEXT provides software and services to complement Samsung's global hardware footprint, combining product development, investment, and M&A under one roof.
Joy Capital
Joy Capital consults to companies and investment funds on strategies to drive the success of entrepreneurial growth businesses in global markets, with a focus on mobile and communications.
What's next for Healthy io?
With the recent influx of capital, Healthy.io is well-positioned to expand its diagnostic portfolio and deepen its penetration into international markets. The strategic focus will likely center on enhancing its AI-driven diagnostic accuracy and broadening the scope of its digital wound management solutions. As the company matures, it is expected to forge deeper partnerships with large-scale health insurers and hospital networks, further embedding its technology into the standard of care for chronic disease management.
The ongoing support from institutional investors suggests a long-term commitment to scaling the company's reach. Future growth will likely involve navigating complex regulatory landscapes in new territories while maintaining the clinical rigor that has become the hallmark of the Healthy.io brand. By continuing to innovate at the edge of mobile imaging and machine learning, the firm is poised to remain a dominant force in the global health technology ecosystem.
